Literature DB >> 8396951

DNA flow cytometric analysis in patients with operable non-small cell lung carcinoma.

P Granone1, G Cardillo, E Rumi, D D'Ugo, C Rumi, S Ciletti, S Margaritora, D Terribile, A Picciocchi.   

Abstract

Fresh surgical specimens of tumors from 60 patients with previously untreated non-small cell lung carcinoma (NSCLC) who underwent radical surgery between January 1991 and October 1992 were investigated by means of flow-cytometry. The nuclear DNA measurement was carried out using a Facscan (Becton, Dickinson, USA). Analysis of the DNA content was performed in all 60 patients whilst cell cycle analysis was possible in 41 cases (68.3%). Forty-two of the 60 cases (70%) were aneuploid and 18 (30%) were diploid. The overall mean value of DNA index was 1.5. Diploid NSCLC were compared with aneuploid tumors: no significant differences in age distribution, sex ratio, histology and staging were found between the two groups (P > 0.05). An S-phase proportion of more than 10% was found in 30 out of 41 patients (73.2%). Early cancer deaths were reported in four patients (6.6%): the aneuploidy rate was very close in these patients (75%) and in the remaining surviving patients (69.6%). An S-phase proportion of more than 10% was found in 100% of early cancer deaths and in 70.2% of the remaining cases; such a difference seems of some importance although it was not statistically significant (P = 0.071). In conclusion, flow-cytometry studies seem to be a useful tool in the understanding of the biological behavior of patients with NSCLC. In the present prospective report there were no significant correlations between DNA measurements and clinical outcome, however, these results suggest that a high S-phase proportion should be seen as a possible prognostic indicator.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396951     DOI: 10.1016/1010-7940(93)90065-j

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer.

Authors:  Genni M Newnham; Matthew Conron; Sueanne McLachlan; Alexander Dobrovic; Hongdo Do; Jason Li; Kenneth Opeskin; Natalie Thompson; Gavin M Wright; David M Thomas
Journal:  BMC Cancer       Date:  2011-03-07       Impact factor: 4.430

2.  Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data.

Authors:  D Choma; J P Daurès; X Quantin; J L Pujol
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

3.  Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer.

Authors:  K Nakagawa; H Tada; A Akashi; T Yasumitsu; K Iuchi; T Taki; K Kodama
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.